Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal Article
Mepolizumab (Nucala) For Severe Eosinophilic Asthma.
TL;DR: Mepolizumab (Nucala) for severe eosinophilic asthma and a second line treatment is in development for moderate to severe asthma patients with a history of severe asthma.
Journal ArticleDOI
Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma
Anne-Noëlle Frix,Florence Schleich,Virginie Paulus,Françoise Guissard,Monique Henket,Renaud Louis +5 more
TL;DR: It is concluded that omalizumab shows effectiveness in severe allergic asthma in a real life setting, by reducing exacerbation rate, improving patient perspective outcomes and airway calibre, together with reducing type-2 airway inflammation.
Journal ArticleDOI
Moving towards precision care for childhood asthma.
TL;DR: The optimal treatment strategy for children with asthma is not yet defined and likely dependent on many patient and disease characteristics, so better definition of asthma phenotypes and better targeting of therapy based on individual patient phenotypes are likely to improve asthma treatment in the future.
Journal ArticleDOI
Moving toward consensus on diagnosis and management of severe asthma in adults
TL;DR: The definition, prevalence and immunopathology of severe asthma is reviewed, the asthma phenotypes, clinical features and comorbidities are described, the diagnosis and personalized asthma treatment are described and a treatment approach based on literature publications, personalized medicine and marketed biologic treatment options is offered.
Journal ArticleDOI
FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma.
Sheila Cabrejos,Ana Moreira,Andreina Ramirez,Santiago Quirce,Gregorio Soto Campos,Ignacio Dávila,Paloma Campo +6 more
TL;DR: The asthma control achieved by patients with severe allergic asthma treated with omalizumab is highlighted, with relevant benefits on the burden of the disease both on patients and the healthcare system.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.